A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer

Sponsored by Pfizer (industry) · PFE — their whole pipeline →. With Merck Sharp & Dohme LLC, Merck KGaA, Darmstadt, Germany, Eli Lilly and Company.

Phase

Phase 2

Status

Active, not recruiting

Study type

Interventional

Design

Randomized · None · Treatment

Enrollment

108actual

Sites

Countries

Australia, Belgium, Canada +12

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2022-07-11

actual

When the study began enrolling

Primary completion

2026-06-19

actual

The date the last participant is measured for the primary outcome — the readout window

Study completion

2027-01-26

estimated

The whole study's end, after follow-up

First posted

2022-02-01

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-07-31

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Metastatic Colorectal Cancer

Interventions

Drug: Encorafenib — also filed as PF-07263896 LGX818 ONO-7702 W0090
Biological: Cetuximab — also filed as Erbitux
Biological: Pembrolizumab — also filed as Keytruda®, MK-3475

Primary outcome

what the primary-completion date above is the date OF

Progression-free Survival (PFS)

measured Duration of study, approximately 45 months

Publications

PMID 37815847 — linked by the registry

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed